Biontech initiates phase 1 clinical trial for malaria vaccine program bnt165

Mainz, germany, december 23, 2022 – biontech se (nasdaq: bntx, “biontech”, "the company") today announced the initiation of a first-in-human phase 1 study with bnt165b1, the first candidate from the company's bnt165 program, to develop a multi-antigen malaria vaccine candidate. biontech will initially evaluate a set of mrna-encoded antigens of the malaria-causing parasite plasmodium falciparum (p. falciparum) to help select the multi-antigen vaccine candidate to proceed to planned later-stage trials. this first clinical trial ( nct05581641 ) will evaluate the safety, tolerability and exploratory immunogenicity of the vaccine candidate bnt165b1. bnt165b1 expresses certain parts of the circumsporozoite protein (csp).
BNTX Ratings Summary
BNTX Quant Ranking